Ironwood Pharma (IRWD) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
November 3, 2015 4:05 PM ESTLINZESS® (linaclotide) prescriptions increased approximately 38% to over 550 thousand in third quarter 2015 compared to third quarter 2014
LINZESS U.S. net sales increased approximately 47% to $117.5 million in third quarter 2015 compared to third quarter 2014
Ironwood revenue increased approximately 134% to $39.6 million in third quarter 2015 compared to third quarter 2014
Multiple positive development milestones including linaclotide 72mcg Phase III data, initiation of Phase IIb linaclotide colonic release trial, and advancement of sGC platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
